MedTrace Logo

Responses Induced by Smoking in Individuals Being Susceptible and Non-Susceptible for Development of COPD

NCT00807469 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2008-12-12

No results posted yet for this study

Summary

COPD is ranked number 3 by the WHO list of important diseases worldwide and is the only disease with increasing mortality. The pathogenesis of cigarette smoke-induced COPD is obscure, therefore more insight is needed to design effective anti-inflammatory agents. We hypothesize that healthy individuals who are susceptible to smoking demonstrate a higher and aberrant inflammatory response to cigarette smoke. This susceptibility is caused by heterogeneous factors and is associated with various polymorphic genes that interact with each other and with the environment.

Objective:

* To define mediators involved in the early induction of COPD in susceptible smokers (and so to define new drug targets)
* To develop new biological and clinical markers for the early diagnosis and monitoring of COPD
* To compare between susceptible and non-susceptible individuals the corticosteroid responsiveness of bronchial epithelial cells in vitro, and to study the mechanisms of smoking-induced corticosteroid unresponsiveness.
* To study the role of candidate genes that may play a role in the development of fixed airway obstruction, and to identify clues for patient's responsiveness to specific drugs.

Conditions

Sponsors & Collaborators

  • University Medical Center Groningen

    collaborator OTHER

  • UMC Utrecht

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Nycomed

    collaborator INDUSTRY

  • Top Institute Pharma

    lead OTHER

Principal Investigators

  • Dirkje Postma, Dr. Prof. MD · UMCG

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2013-01-31
Completion
2015-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00807469 on ClinicalTrials.gov